Corteva

Chuck Magro took over as CEO from Jim Collins in 2021 and leads capital-allocation decisions including the $2 billion share buyback program authorized in 2023. Magro was previously CEO of Nutrien, the Canadian fertilizer giant, giving him direct operational experience in agricultural inputs. The board includes directors with backgrounds at companies including Dow and DuPont.

Corteva is the only large-cap publicly traded agriculture company that is not part of a pharmaceutical, chemical, or industrial conglomerate. Bayer's crop science division operates inside a larger healthcare group, while Syngenta was acquired by Sinochem and taken private. That independence gives Corteva management more direct accountability but leaves it more exposed to commodity cycles without a diversified parent's balance sheet to smooth earnings.

The company reports through two segments: Seed, which includes the Pioneer and Brevant brands and contributed roughly half of revenue in 2023, and Crop Protection, which sells herbicides, fungicides, insecticides, and nitrogen stabilizers. Enlist weed-control systems and Arylex herbicides are key product families within the Crop Protection unit. The company also licenses germplasm and traits to other seed companies, which provides a royalty revenue stream.

Pioneer Hi-Bred, founded in 1926 in Iowa and acquired by DuPont in 1999, is the operational heart of Corteva's seed segment. The brand holds leading market shares in North American corn and soybeans and carries significant pricing power with farmers. The Johnston, Iowa campus where seed R&D and trait development work occurs employs thousands of scientists and functions as the company's intellectual property engine.

Yes. Several of the company's foundational biotech trait patents—particularly on the insect-resistance and herbicide-tolerance traits embedded in its corn and soybean portfolios—begin expiring in the second half of the 2020s. Management has acknowledged this in regulatory filings and is investing in next-generation gene-edited traits and biologicals as replacements, but the transition is a significant factor for institutional investors tracking the stock.

Corteva has invested substantially in gene editing, including CRISPR-based techniques, through its internal R&D program and through partnerships. It was one of the early holders of foundational CRISPR-Cas9 intellectual property for agricultural applications, alongside the Broad Institute. The company's public messaging emphasizes gene editing as a pipeline differentiator from older transgenic GMO approaches, though commercial products using gene editing are still scaling.

North America is the largest market, dominated by the Pioneer U.S. corn and soybean franchise, but Latin America—particularly Brazil—is the fastest-growing and most strategically important region. Corteva holds one of the leading market positions in Brazilian corn seed, driven by its tropical germplasm adapted for the safrinha (second-crop) growing system. Europe, the Middle East, Africa, and Asia-Pacific together represent a smaller but growing share of revenue.